Research in social & administrative pharmacy : RSAP · 2025
Modelling the impact of changes to prescription medicine cost-sharing schemes among middle aged and older adults.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Larkin James, Prendergast Ciaran, Murry Logan T, Flood Michelle, Clyne Barbara, Burke Sara, Keegan Conor, Boland Fiona, Fahey Tom, Persaud Nav, Kenny Rose Anne, Moriarty Frank
Аннотация
OBJECTIVE: To assess impacts of government changes to prescription medicine co-payments on individuals' out-of-pocket expenditure.
METHODS: Participants were community-dwelling adults primarily aged ≥56 years from The Irish Longitudinal Study on Ageing study. Ireland has two prescription cost-sharing schemes: the General Medical Services (GMS) scheme (primarily low-income populations), involving low monthly payment caps and co-payments, and the Drugs Payment Scheme (DPS) (for others), with higher caps and no co-payment limit. We modelled changes to these schemes implemented between 2016 and 2022 using 2016 data, assessing out-of-pocket prescription medicine expenditure using descriptive statistics and regression analysis.
RESULTS: Among 4,155 participants with out-of-pocket prescription medicine expenditure, estimated mean annual prescription medicine expenditure for GMS-eligible participants reduced from €117 (95 %CI = €114-120) to €55 (95 %CI = €54-€56) due to post-2016 changes. For DPS-eligible participants, it reduced from €719 (95 %CI = €694-€744) to €555 (95 %CI = €541-€569).
CONCLUSIONS: Co-payment changes led to average savings of €62 for GMS-eligible participants and €174 for DPS-eligible participants. Although absolute savings were smaller for GMS participants, as the scheme is primarily for low-income populations and the relative expenditure reduction was greater for GMS- than DPS-eligible participants, these savings were likely more impactful for GMS-eligible participants. Further reductions in monthly caps and co-payment charges, particularly for low-income populations, warrant consideration.
METHODS: Participants were community-dwelling adults primarily aged ≥56 years from The Irish Longitudinal Study on Ageing study. Ireland has two prescription cost-sharing schemes: the General Medical Services (GMS) scheme (primarily low-income populations), involving low monthly payment caps and co-payments, and the Drugs Payment Scheme (DPS) (for others), with higher caps and no co-payment limit. We modelled changes to these schemes implemented between 2016 and 2022 using 2016 data, assessing out-of-pocket prescription medicine expenditure using descriptive statistics and regression analysis.
RESULTS: Among 4,155 participants with out-of-pocket prescription medicine expenditure, estimated mean annual prescription medicine expenditure for GMS-eligible participants reduced from €117 (95 %CI = €114-120) to €55 (95 %CI = €54-€56) due to post-2016 changes. For DPS-eligible participants, it reduced from €719 (95 %CI = €694-€744) to €555 (95 %CI = €541-€569).
CONCLUSIONS: Co-payment changes led to average savings of €62 for GMS-eligible participants and €174 for DPS-eligible participants. Although absolute savings were smaller for GMS participants, as the scheme is primarily for low-income populations and the relative expenditure reduction was greater for GMS- than DPS-eligible participants, these savings were likely more impactful for GMS-eligible participants. Further reductions in monthly caps and co-payment charges, particularly for low-income populations, warrant consideration.